BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
BlossomHill Therapeutics announced updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643, a novel OMNI-EGFR inhibitor targeting EGFR-mutant non-small cell lung cancer (NSCLC) with secondary resistance mutations including C797S. Data will be presented at the 2026 World Conference on Lung Cancer. BH-30643 has received FDA Fast Track design…